[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016007805A2 - receptor de antígeno quimérico - Google Patents

receptor de antígeno quimérico

Info

Publication number
BR112016007805A2
BR112016007805A2 BR112016007805A BR112016007805A BR112016007805A2 BR 112016007805 A2 BR112016007805 A2 BR 112016007805A2 BR 112016007805 A BR112016007805 A BR 112016007805A BR 112016007805 A BR112016007805 A BR 112016007805A BR 112016007805 A2 BR112016007805 A2 BR 112016007805A2
Authority
BR
Brazil
Prior art keywords
antigen receptor
chimeric antigen
cell
domain
car
Prior art date
Application number
BR112016007805A
Other languages
English (en)
Inventor
DRAPER Ben
Yong Kwee
LEE Lydia
PULÉ Martin
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49679854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016007805(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of BR112016007805A2 publication Critical patent/BR112016007805A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo de patente de invenção de: “receptor de antígeno quimérico”. a presente invenção proporciona um receptor antigênico quimérico (car), que compreende: (i) um domínio de ligação ao antígeno de maturação das células b (bcma), o qual compreende pelo menos parte de um ligante indutor de proliferação (april); (ii) um domínio espaçador (iii) um domínio transmembranar; e (iv) um domínio de sinalização intracelular de células t. a invenção também proporciona a utilização de uma célula t que expressa um tal car no tratamento de doenças mediadas por células plasmáticas, tais como o mieloma múltiplo
BR112016007805A 2013-10-10 2014-10-10 receptor de antígeno quimérico BR112016007805A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1317929.6A GB201317929D0 (en) 2013-10-10 2013-10-10 Chimeric antigen receptor
PCT/GB2014/053058 WO2015052538A1 (en) 2013-10-10 2014-10-10 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
BR112016007805A2 true BR112016007805A2 (pt) 2017-12-05

Family

ID=49679854

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007805A BR112016007805A2 (pt) 2013-10-10 2014-10-10 receptor de antígeno quimérico

Country Status (17)

Country Link
US (4) US10160794B2 (pt)
EP (1) EP3055326B1 (pt)
JP (2) JP6632073B2 (pt)
KR (1) KR20160067177A (pt)
CN (1) CN105658671B (pt)
AU (1) AU2014333564B2 (pt)
BR (1) BR112016007805A2 (pt)
CA (1) CA2926560A1 (pt)
CL (1) CL2016000734A1 (pt)
ES (1) ES2918626T3 (pt)
GB (1) GB201317929D0 (pt)
HK (1) HK1222186A1 (pt)
IL (1) IL244784A0 (pt)
MX (1) MX2016004362A (pt)
RU (2) RU2684713C2 (pt)
SG (1) SG11201602414SA (pt)
WO (1) WO2015052538A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
AU2015221933B2 (en) 2014-02-27 2019-09-12 Autolus Limited APRIL variants
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
JP6698546B2 (ja) 2014-04-14 2020-05-27 セレクティスＣｅｌｌｅｃｔｉｓ 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体
CN107531801B (zh) 2015-01-26 2021-11-12 塞勒克提斯公司 用于分选/清除工程化的免疫细胞的mAb驱动的嵌合抗原受体系统
KR102349475B1 (ko) 2015-04-13 2022-01-11 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
IL303905A (en) 2015-05-18 2023-08-01 Tcr2 Therapeutics Inc Compositions and methods for TCR programming using fusion proteins
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
AU2016302881B2 (en) 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US11090334B2 (en) 2016-01-29 2021-08-17 Med Manor Organics (P) Ltd. Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
BR112018073673A2 (pt) 2016-05-20 2019-02-26 Eli Lilly And Company terapia de combinação com inibidores de notch e de pd-1 ou pd-l1
CN109641012A (zh) * 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP3848392A1 (en) 2016-10-07 2021-07-14 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2017353427A1 (en) 2016-11-02 2019-05-16 Bristol-Myers Squibb Company Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
US20190352409A1 (en) * 2016-11-11 2019-11-21 Autolus Limited Chimeric antigen receptor
EP3544996A2 (en) 2016-11-22 2019-10-02 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2018207300B2 (en) * 2017-01-10 2023-08-24 The General Hospital Corporation T cells expressing a chimeric antigen receptor
SG11201907580SA (en) * 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
GB201709508D0 (en) * 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
CA3071495A1 (en) * 2017-08-02 2019-02-07 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
EP3706754A1 (en) * 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
AU2019206573B2 (en) * 2018-01-10 2024-06-06 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor
TWI728308B (zh) * 2018-02-01 2021-05-21 大陸商南京馴鹿醫療技術有限公司 一種結合ｂｃｍａ的嵌合抗原受體（ｃａｒ）及其應用
WO2019180724A1 (en) * 2018-03-23 2019-09-26 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing membrane-bound il-10
GB201807693D0 (en) 2018-05-11 2018-06-27 Autolus Ltd Cell
CU20200089A7 (es) 2018-06-01 2021-07-02 Novartis Ag Moléculas de unión contra bcma
CA3103610A1 (en) 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
US12049510B2 (en) 2018-09-27 2024-07-30 Autolus Limited Chimeric antigen receptor
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
EP3893923A2 (en) 2018-12-14 2021-10-20 Autolus Limited Cell
GB201904160D0 (en) 2019-03-26 2019-05-08 Autolus Ltd Cell
WO2020172643A2 (en) * 2019-02-21 2020-08-27 Luk John M Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
EP3941589A1 (en) 2019-03-21 2022-01-26 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
GB201904971D0 (en) 2019-04-08 2019-05-22 Autolus Ltd Cell
GB201906202D0 (en) 2019-05-02 2019-06-19 Autolus Ltd Cell
WO2020224606A1 (zh) 2019-05-07 2020-11-12 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
CN113784733B (zh) 2019-05-07 2024-09-06 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
CN110592015A (zh) * 2019-09-27 2019-12-20 中国科学院西双版纳热带植物园 一种诱导增强cik细胞的滇重楼多糖组合物及其应用
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294615B6 (cs) * 1997-09-12 2005-02-16 Apotech R & D Sa Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
DK1297013T3 (da) * 2000-04-27 2006-12-27 Biogen Idec Inc Anvendelse af TACI som antitumormiddel
CA2419661A1 (en) * 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
CN101683520A (zh) * 2002-04-09 2010-03-31 比奥根艾迪克Ma公司 用于治疗tweak相关病症的方法
AU2003270715A1 (en) * 2002-09-19 2004-04-08 Biogen Idec Ma Inc. Improved methods for preparing highly active april ligand polypeptides
US7947805B2 (en) * 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
KR20220029757A (ko) * 2012-04-11 2022-03-08 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2015221933B2 (en) * 2014-02-27 2019-09-12 Autolus Limited APRIL variants
US20190352409A1 (en) 2016-11-11 2019-11-21 Autolus Limited Chimeric antigen receptor
GB201709508D0 (en) 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
AU2019206573B2 (en) * 2018-01-10 2024-06-06 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor

Also Published As

Publication number Publication date
US20160237139A1 (en) 2016-08-18
CA2926560A1 (en) 2015-04-16
AU2014333564A1 (en) 2016-04-28
US10160794B2 (en) 2018-12-25
WO2015052538A1 (en) 2015-04-16
US20210101959A1 (en) 2021-04-08
KR20160067177A (ko) 2016-06-13
GB201317929D0 (en) 2013-11-27
MX2016004362A (es) 2016-10-13
RU2016117383A (ru) 2017-11-15
JP2019052190A (ja) 2019-04-04
US20190100571A1 (en) 2019-04-04
SG11201602414SA (en) 2016-04-28
US20240076352A1 (en) 2024-03-07
EP3055326A1 (en) 2016-08-17
EP3055326B1 (en) 2022-04-20
JP2016538830A (ja) 2016-12-15
AU2014333564B2 (en) 2018-09-27
RU2019102382A (ru) 2019-02-22
RU2016117383A3 (pt) 2018-05-22
ES2918626T3 (es) 2022-07-19
HK1222186A1 (zh) 2017-06-23
IL244784A0 (en) 2016-04-21
CN105658671A (zh) 2016-06-08
CN105658671B (zh) 2021-08-27
JP6632073B2 (ja) 2020-01-15
RU2684713C2 (ru) 2019-04-11
US10919951B2 (en) 2021-02-16
CL2016000734A1 (es) 2017-05-19

Similar Documents

Publication Publication Date Title
BR112016007805A2 (pt) receptor de antígeno quimérico
PH12014502406A1 (en) Anti-il-23p19 antibodies
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
EA201590139A1 (ru) Шприц
MX347164B (es) Anticuerpos anti-il-36r.
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12016501366A1 (en) Novel anti-baff antibodies
MX2023006416A (es) Anticuerpos, usos y metodos.
JO3755B1 (ar) تركيبات تستوستيرون
MY175418A (en) Compositions comprising anti-cd38 antibodies and carfilzomib
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX370673B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
TN2014000207A1 (en) Anti il-36r antibodies
UA78669U (en) 5,11-di(3,4-dimethylphenyl)-8-thioxo-13-(2-chlorophenyl)-3,5,7,11-tetraazatricyclo[7,3,1,02,7]tridec-2-ene-1,9-dicarbonitrile
IN2013CH00453A (pt)
UA78284U (en) 5,11- dibenzyl -8-thioxo-13-(2-chlorophenyl)-3,5,7,11- tetraazatricyclo[7.3.1.02,7]tridec-2-ene-1,9-dicarbonitrile

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCL BUSINESS LTD (GB)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements